Acquired identifiable intangible assets and goodwill, Amounts

No definition available.

Name:	jnj_AcquiredIndefiniteIntangibleAssetsAndGoodwillAmounts
Namespace Prefix:	jnj_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Business Combinations And Divestitures Textuals Abstract.

+ References

No definition available.

+ Details

Name:	jnj_BusinessCombinationsAndDivestituresTextualsAbstract
Namespace Prefix:	jnj_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Discount rate used in probability of success in research and development.

+ References

No definition available.

+ Details

Name:	jnj_DiscountRateUsedInProbabilityOfSuccessInResearchAndDevelopment
Namespace Prefix:	jnj_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Probability of success

+ References

No definition available.

+ Details

Name:	jnj_ProbabilityOfSuccess
Namespace Prefix:	jnj_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

purchased in process research and development

+ References

No definition available.

+ Details

Name:	jnj_PurchasedInProcessResearchAndDevelopment
Namespace Prefix:	jnj_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2443-110228

+ Details

Name:	us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name:	us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name:	us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.

+ References

No definition available.

+ Details

Name:	us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_XO1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_CovagenAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_AragonPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_SynthesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_OCDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=jnj_NoviraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Business Combinations and Divestitures (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 03, 2016	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)	$ 954	$ 2,129	$ 835
Business Combinations and Divestitures (Textuals) [Abstract]
Gain (Loss) on Disposition of Assets	2,600	2,400	100
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed	220	38	193
Business Combination, Contingent Consideration, Liability	210
Acquired indefinite lived asset, amounts	1,173	2,069	941
Payments to Acquire Businesses, Net of Cash Acquired	$ 954	$ 2,129	$ 835
XO1 [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Discount Rate Used in Probability of Success in Research and Development	11.75%
Probability Of Success	36.00%
Alios Biopharma [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Discount Rate Used in Probability of Success in Research and Development		11.40%
Probability Of Success		60.00%
Covagen AG [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Discount Rate Used in Probability of Success in Research and Development		12.50%
Probability Of Success		26.00%
Aragon Pharmaceuticals, Inc [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Discount Rate Used in Probability of Success in Research and Development			15.50%
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 350
Synthes, Inc [Member]
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)				$ 20,200
OCD [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Gain (Loss) on Disposition of Assets		$ 1,900
Proceeds from Sales of Business, Affiliate and Productive Assets		4,000
Purchased In-Process Research And Development [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
purchased in process research and development	$ 839	1,913	831
Purchased In-Process Research And Development [Member] \| XO1 [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
purchased in process research and development	$ 360
Purchased In-Process Research And Development [Member] \| Novira [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Discount Rate Used in Probability of Success in Research and Development	16.00%
Probability Of Success	51.00%
purchased in process research and development	$ 396
Purchased In-Process Research And Development [Member] \| Alios Biopharma [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
purchased in process research and development		1,688
Purchased In-Process Research And Development [Member] \| Covagen AG [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
purchased in process research and development		$ 225
Purchased In-Process Research And Development [Member] \| Aragon Pharmaceuticals, Inc [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
purchased in process research and development			$ 810
Minimum [Member] \| Aragon Pharmaceuticals, Inc [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Probability Of Success			37.00%
Maximum [Member] \| Aragon Pharmaceuticals, Inc [Member]
Business Combinations and Divestitures (Textuals) [Abstract]
Probability Of Success			52.00%